Zacks Investment Research
21 Jul 2026, 22:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Medtronic currently carries a Zacks Rank of #4 (Sell). — A 'Sell' rating from a proprietary model focused on estimate revisions suggests negative near-term price momentum.
-0.60Medtronic is projected to report an EPS of $1.39 and revenue of $9.48 billion for the quarter ending September 1, 2026, representing year-over-year growth of roughly 10%. — Double-digit growth projections for both top and bottom lines are fundamentally positive.
+0.40Medtronic's Forward P/E ratio of 14.01 is at a discount compared to the industry average of 19.35. — A significant discount relative to peers may suggest the stock is undervalued, attracting value investors.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Medtronic shares fell 1.13% in the latest session, underperforming the S&P 500, Dow, and Nasdaq. — Short-term price weakness and negative relative performance indicate a lack of immediate buying conviction.
Which stocks this story touches
The company is currently assigned a Zacks Rank of #4 (Sell) and its stock fell short of the S&P 500 in the latest session.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
